Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma
出版年份 2022 全文链接
标题
Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma
作者
关键词
-
出版物
Frontiers in Oncology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-12-22
DOI
10.3389/fonc.2022.1024677
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report
- (2022) Jing Wu et al. Annals of Translational Medicine
- Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2021) Binghe Xu et al. LANCET ONCOLOGY
- Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
- (2021) Munawar Anwar et al. CLINICAL CANCER RESEARCH
- Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer
- (2021) Jie Gao et al. MEDICINE
- Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
- (2021) Laure Thouvenin et al. Gynecologic Oncology Reports
- Potential effectiveness of combining bevacizumab with paclitaxel for treating HER2-positive metastatic breast cancer
- (2021) Mai Hamada-Nishimoto et al. International Cancer Conference Journal
- Options for the Treatment of Mucinous Ovarian Carcinoma
- (2021) Olivia Craig et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma
- (2021) Robert L. Hollis et al. Cancers
- Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
- (2020) Caicun Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer
- (2020) Shaily Arora et al. ONCOLOGIST
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
- (2019) Fei Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma
- (2019) Katherine C. Kurnit et al. OBSTETRICS AND GYNECOLOGY
- Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report
- (2019) Le-Tian Huang et al. Frontiers in Oncology
- A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP
- (2018) Toshimi Takano et al. BREAST
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
- (2018) Y Wang et al. ANNALS OF ONCOLOGY
- Comparison of stage III mucinous and serous ovarian cancer: a case-control study
- (2018) Zeliha Firat Cuylan et al. Journal of Ovarian Research
- Relatively Poor Survival of Mucinous Ovarian Carcinoma in Advanced Stage
- (2017) Michiel Simons et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2017) Fei Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene set-based analysis of mucinous ovarian carcinoma
- (2017) Chia-Ming Chang et al. Taiwanese Journal of Obstetrics & Gynecology
- Natural history and outcome of mucinous carcinoma of the ovary
- (2011) Maria B. Schiavone et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies
- (2011) D. Faratian et al. CLINICAL CANCER RESEARCH
- HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
- (2009) Jessica N McAlpine et al. BMC CANCER
- The Future of Targeted Therapies in Ovarian Cancer
- (2009) S. Banerjee et al. ONCOLOGIST
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started